News - Vytorin

Filter

Current filters:

Vytorin

Popular Filters

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages

15-02-2013

US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute

30-04-2012

US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

US FDA mixed views on Vytorin and Zetia

26-01-2012

US drug giant Merck & Co (NYSE: MRK) yesterday received Food and Drug Administration approval to update…

Cardio-vascularMerck & CoNephrology and HepatologyNorth AmericaPharmaceuticalRegulationVytorinZetia

FDA panel gives unanimous backing for Merck & Co’s Vytorin for some kidney disease patients

04-11-2011

US drug giant Merck & Co (NYSE: MRK) said yesterday that the Endocrinologic and Metabolic Drugs Advisory…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationVytorin

Back to top